ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.73 CNY | -1.07% |
|
-4.78% | +47.56% |
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- This company will be of major interest to investors in search of a high dividend stock.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +47.56% | 1.54B | - | ||
| +43.31% | 6.19B | B- | ||
| -16.99% | 4.48B | C+ | ||
| +6.39% | 3.29B | C | ||
| -13.10% | 3.12B | B- | ||
| -4.17% | 2.5B | - | D+ | |
| +45.47% | 1.94B | - | ||
| -9.11% | 1.68B | - | - | |
| -2.09% | 1.64B | - | - | |
| -12.50% | 1.56B | C- |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 300181 Stock
- Ratings Zhejiang Jolly Pharmaceutical Co.,LTD